Molecular imaging of fibrosis: recent advances and future directions
Sydney B. Montesi,1 Pauline Désogère,2,3,4 Bryan C. Fuchs,5 and Peter Caravan2,3,4
1Division of Pulmonary and Critical Care Medicine and
2Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
3Athinoula A. Martinos Center for Biomedical Imaging and
4Institute for Innovation in Imaging, Massachusetts General Hospital, Boston, Massachusetts, USA.
5Division of Surgical Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USA.
Address correspondence to: Peter Caravan, 149 Thirteenth Street, Suite 2301, Charlestown, MA 02129, USA. Phone: 617.643.0193; Email: caravan@nmr.mgh.harvard.edu.
Find articles by Montesi, S. in: JCI | PubMed | Google Scholar
1Division of Pulmonary and Critical Care Medicine and
2Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
3Athinoula A. Martinos Center for Biomedical Imaging and
4Institute for Innovation in Imaging, Massachusetts General Hospital, Boston, Massachusetts, USA.
5Division of Surgical Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USA.
Address correspondence to: Peter Caravan, 149 Thirteenth Street, Suite 2301, Charlestown, MA 02129, USA. Phone: 617.643.0193; Email: caravan@nmr.mgh.harvard.edu.
Find articles by Désogère, P. in: JCI | PubMed | Google Scholar
1Division of Pulmonary and Critical Care Medicine and
2Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
3Athinoula A. Martinos Center for Biomedical Imaging and
4Institute for Innovation in Imaging, Massachusetts General Hospital, Boston, Massachusetts, USA.
5Division of Surgical Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USA.
Address correspondence to: Peter Caravan, 149 Thirteenth Street, Suite 2301, Charlestown, MA 02129, USA. Phone: 617.643.0193; Email: caravan@nmr.mgh.harvard.edu.
Find articles by Fuchs, B. in: JCI | PubMed | Google Scholar
1Division of Pulmonary and Critical Care Medicine and
2Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
3Athinoula A. Martinos Center for Biomedical Imaging and
4Institute for Innovation in Imaging, Massachusetts General Hospital, Boston, Massachusetts, USA.
5Division of Surgical Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USA.
Address correspondence to: Peter Caravan, 149 Thirteenth Street, Suite 2301, Charlestown, MA 02129, USA. Phone: 617.643.0193; Email: caravan@nmr.mgh.harvard.edu.
Find articles by
Caravan, P.
in:
JCI
|
PubMed
|
Google Scholar
|
First published January 2, 2019 - More info
J Clin Invest. 2019;129(1):24–33. https://doi.org/10.1172/JCI122132.
Copyright © 2019, American Society for Clinical Investigation
Fibrosis, the progressive accumulation of connective tissue that occurs in response to injury, causes irreparable organ damage and may result in organ failure. The few available antifibrotic treatments modify the rate of fibrosis progression, but there are no available treatments to reverse established fibrosis. Thus, more effective therapies are urgently needed. Molecular imaging is a promising biomedical methodology that enables noninvasive visualization of cellular and subcellular processes. It provides a unique means to monitor and quantify dysregulated molecular fibrotic pathways in a noninvasive manner. Molecular imaging could be used for early detection, disease staging, and prognostication, as well as for assessing disease activity and treatment response. As fibrotic diseases are often molecularly heterogeneous, molecular imaging of a specific pathway could be used for patient stratification and cohort enrichment with the goal of improving clinical trial design and feasibility and increasing the ability to detect a definitive outcome for new therapies. Here we review currently available molecular imaging probes for detecting fibrosis and fibrogenesis, the active formation of new fibrous tissue, and their application to models of fibrosis across organ systems and fibrotic processes. We provide our opinion as to the potential roles of molecular imaging in human fibrotic diseases.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Individual online subscriptions ordered from September 1st on will receive access for the remainder of current year as well as for the full following year subscription term.
- Print subscription
- $830
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)